Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)

Trial Profile

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2018

At a glance

  • Drugs Dotinurad (Primary) ; Febuxostat
  • Indications Hyperuricaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Mochida Pharmaceutical
  • Most Recent Events

    • 21 Sep 2018 Status changed from recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 23 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top